Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP

"Protalex, Inc., a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study), the Company has initiated enrollment in the third cohort of this dose-escalating study. The first patient in the third cohort was recently dosed at 12.0 µg/kg, double that of the second dose cohort of 6.0 µg/kg. PRTX-100 has been granted Orphan Drug Designation in the U.S. and in Europe for the treatment of ITP."

- From Protalex press release

Read More


back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo